Yahoo Finance

Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting

REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of ...
Nasdaq

Bolt Biotherapeutics Reports Positive Phase 1 Results for BDC-3042, Demonstrating Safety and Anti-Tumor Activity in Cancer Patients

BDC-3042 demonstrated a favorable safety profile, with no dose-limiting toxicities or serious drug-related adverse events reported, which is significant for advancing clinical development. The drug ...
Yahoo Finance

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid ...
Nasdaq

Bolt Biotherapeutics Updates on Clinical Trials and Financial Results, Anticipates Milestones for BDC-4182 and BDC-3042

Bolt Biotherapeutics reported clinical updates and financial results, highlighting BDC-4182's upcoming trial and completed enrollment for BDC-3042. Bolt Biotherapeutics has announced significant ...
Seeking Alpha

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in ...
Investing

ChinaAMC Bitcoin ETF (3042)

Assess whether 3042 fits your portfolio by analysing key metrics including dividend yield (where relevant), expense ratio, holdings composition and long-term performance trends. Compare asset ...